VEGFA and hepatocellular carcinoma: Bevacizumab, an extensively characterised antiangiogenetic agent thanks to 15 years of use in multiple cancer indications,15 has also shown a signal of activity and is well tolerated as monotherapy in patients with advanced HCC.16,17 Bleeding is a known safety concern in cancer patients who receive VEGF- or VEGF receptor-targeted therapies18,19 and may represent a special concern in HCC patients.